Nothing Special   »   [go: up one dir, main page]

ES2186796T3 - Procedimiento para el tratamiento del asma alergica. - Google Patents

Procedimiento para el tratamiento del asma alergica.

Info

Publication number
ES2186796T3
ES2186796T3 ES96926134T ES96926134T ES2186796T3 ES 2186796 T3 ES2186796 T3 ES 2186796T3 ES 96926134 T ES96926134 T ES 96926134T ES 96926134 T ES96926134 T ES 96926134T ES 2186796 T3 ES2186796 T3 ES 2186796T3
Authority
ES
Spain
Prior art keywords
treatment
allergic asthma
procedure
ige
antigonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96926134T
Other languages
English (en)
Other versions
ES2186796T5 (es
Inventor
Robert B Fick Jr
Paula M Jardieu
Monika B Schoenhoff
Steven J Shire
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24021032&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2186796(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of ES2186796T3 publication Critical patent/ES2186796T3/es
Application granted granted Critical
Publication of ES2186796T5 publication Critical patent/ES2186796T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

SE DESCRIBEN PROCEDIMIENTOS PARA EL TRATAMIENTO DEL ASMA ALERGICO CON ANTAGONISTAS DE IGE, INCLUYENDO ANTICUERPOS ANTI IGE, VARIANTES DE IGE, ANTAGONISTAS PEPTIDICOS, PEPTIDOMIMETICOS Y OTRAS MOLECULAS PEQUEÑAS.
ES96926134T 1995-07-27 1996-07-24 Procedimientos para el tratamiento del asma alergica. Expired - Lifetime ES2186796T5 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50801495A 1995-07-27 1995-07-27
US508014 1995-07-27

Publications (2)

Publication Number Publication Date
ES2186796T3 true ES2186796T3 (es) 2003-05-16
ES2186796T5 ES2186796T5 (es) 2009-04-01

Family

ID=24021032

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96926134T Expired - Lifetime ES2186796T5 (es) 1995-07-27 1996-07-24 Procedimientos para el tratamiento del asma alergica.

Country Status (16)

Country Link
EP (1) EP0841946B2 (es)
JP (1) JP4153560B2 (es)
CN (2) CN101172100A (es)
AR (1) AR003468A1 (es)
AT (1) ATE225185T1 (es)
AU (1) AU715338B2 (es)
CA (1) CA2226624C (es)
DE (1) DE69624116T3 (es)
DK (1) DK0841946T4 (es)
ES (1) ES2186796T5 (es)
IL (1) IL122733A (es)
MX (1) MX9800760A (es)
PT (1) PT841946E (es)
RU (1) RU2229288C2 (es)
WO (1) WO1997004807A1 (es)
ZA (2) ZA966075B (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6991790B1 (en) 1997-06-13 2006-01-31 Genentech, Inc. Antibody formulation
WO1999045777A1 (en) * 1998-03-10 1999-09-16 The Children's Hospital Of Philadelphia Compositions and methods for treatment of asthma
US6299875B1 (en) * 1998-06-04 2001-10-09 Panacea Pharmaceuticals, Llc Methods to block IGE binding to cell surface receptors of mast cells
US6913749B2 (en) 1998-11-02 2005-07-05 Resistentia Pharmaceuticals Ab Immunogenic polypeptides for inducing anti-self IgE responses
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
SI1324776T2 (en) * 2000-10-12 2018-06-29 Genentech, Inc. Concentrated protein formulations with reduced viscosity
BRPI0316092B8 (pt) 2002-11-08 2021-05-25 Ablynx Nv anticorpos de domínio único direcionados contra o fator de necrose tumoral alfa e usos para os mesmos
MXPA05004955A (es) 2002-11-08 2005-11-17 Ablynx Nv Anticuerpos de region unica dirigidos contra el factor-alfa de necrosis de tumor y usos de estos.
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
DE202006020194U1 (de) * 2006-03-01 2007-12-06 Bioceuticals Arzneimittel Ag G-CSF-Flüssigformulierung
US20100311604A1 (en) * 2007-01-29 2010-12-09 Valtion Teknillinen Tutkimuskeskus Method for producing novel ige based reagents
AR065368A1 (es) 2007-02-15 2009-06-03 Astrazeneca Ab Anticuerpos para moleculas de ige
EP2052736A1 (en) * 2007-10-26 2009-04-29 Nycomed Danmark ApS Parathyroid hormone formulations und uses thereof
CN105126099A (zh) * 2007-12-21 2015-12-09 弗·哈夫曼-拉罗切有限公司 抗体制剂
CN101903030A (zh) * 2007-12-21 2010-12-01 灵感生物制药学有限公司 含海藻糖的稳定化因子ix制剂
AR073997A1 (es) * 2008-10-29 2010-12-15 Wyeth Corp Formulaciones de moleculas de union a antigeno de dominio unico. metodo. kit
JP6113404B2 (ja) 2008-10-29 2017-04-12 アブリンクス エン．ヴェー． 単一ドメイン抗原結合分子の精製方法
HUE038405T2 (hu) 2009-12-15 2018-10-29 Ascendis Pharma Endocrinology Div A/S Átmenetileg polimer hordozóhoz kapcsolt száraz növekedési hormon készítmény
EP4450523A2 (en) 2010-04-02 2024-10-23 Amunix Pharmaceuticals, Inc. Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
CN102533704A (zh) * 2010-12-30 2012-07-04 上海雅心生物技术有限公司 即配即用型的胰蛋白酶制剂
PL2691112T3 (pl) * 2011-03-31 2018-09-28 Merck Sharp & Dohme Corp. Stabilne preparaty przeciwciał przeciw ludzkiemu receptorowi programowanej śmierci pd-1 i terapie powiązane
US20140302021A1 (en) * 2011-10-25 2014-10-09 Onclave Therapeutics Limited Antibody formulations and methods
BR112016006455A2 (pt) * 2013-09-27 2017-08-01 Hanmi Pharm Ind Co Ltd ?formulação de conjugado de hormônio de crescimento humano de ação prolongada?
CN104707146B (zh) * 2013-12-16 2019-04-16 浙江海正药业股份有限公司 一种含有阿达木单抗的药物组合物
EP3653227B9 (en) 2014-11-18 2023-03-08 Ascendis Pharma Endocrinology Division A/S Novel polymeric hgh prodrugs
WO2016079302A1 (en) 2014-11-21 2016-05-26 Ascendis Pharma Growth Disorders Division A/S Long-acting growth hormone dosage forms
GB201610198D0 (en) 2016-06-10 2016-07-27 Ucb Biopharma Sprl Anti-ige antibodies
CN110913906A (zh) 2017-05-02 2020-03-24 默沙东公司 抗lag3抗体的制剂和抗lag3抗体与抗pd-1抗体的共制剂
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
UA125971C2 (uk) 2017-07-25 2022-07-20 Джянгсу Хенгруй Медісін Ко., Лтд. Фармацевтична композиція, яка містить протеїновий комплекс il-15, та її застосування
CR20200394A (es) * 2018-02-09 2020-11-05 Genentech Inc Métodos terapéuticos y diagnósticos para enfermedades inflrmatorias mediadas por mostocitos
CN110732023B (zh) * 2018-07-18 2023-06-16 江苏恒瑞医药股份有限公司 一种her2抗体药物组合物及其用途
BR112023000400A2 (pt) 2020-07-10 2023-03-21 Shanghai Jemincare Pharmaceutical Co Ltd Anticorpo anti-ige engenheirado e aplicação do mesmo
TW202409078A (zh) * 2022-07-18 2024-03-01 中國大陸商蘇州創勝醫藥集團有限公司 穩定之包含抗gremlin1抗體的藥物製劑

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3729863A1 (de) * 1987-09-05 1989-03-16 Boehringer Mannheim Gmbh Stabilisierte erythropoietin-lyophilisate
AU616916B2 (en) * 1987-11-20 1991-11-14 Kissei Pharmaceutical Co. Ltd. 4h-quinolizin-4-one compounds exhibiting therapeutic activities
DE3853636T3 (de) * 1987-12-31 1999-04-08 Tanox Biosystems, Inc., Houston, Tex. Antigene epitope, die sich ausschliesslich auf ige-tragenden b-lymphocyten befinden.
AU3923293A (en) * 1992-03-20 1993-10-21 Immunet Human monoclonal antibodies and methods for human monoclonal antibody production
JPH07118168A (ja) * 1993-10-19 1995-05-09 Tomoyasu Ra ＩｇＥ産生抑制剤
DE69333484T2 (de) * 1992-09-24 2005-03-24 Novartis Ag Umgestaltete monoklonale Antikörper gegen ein Immunglobulinisotyp
DE4344824C1 (de) * 1993-12-28 1995-08-31 Immuno Ag Hochkonzentriertes Immunglobulin-Präparat und Verfahren zu seiner Herstellung

Also Published As

Publication number Publication date
CN101172099B (zh) 2012-02-15
DE69624116D1 (de) 2002-11-07
EP0841946B1 (en) 2002-10-02
MX9800760A (es) 1998-04-30
ZA966075B (en) 1998-01-19
AU6638196A (en) 1997-02-26
IL122733A (en) 2001-09-13
DE69624116T3 (de) 2009-07-09
DK0841946T3 (da) 2003-02-10
CN101172099A (zh) 2008-05-07
JPH11510172A (ja) 1999-09-07
DK0841946T4 (da) 2009-02-16
ZA966240B (en) 1998-01-23
CA2226624C (en) 2013-07-16
AR003468A1 (es) 1998-08-05
JP4153560B2 (ja) 2008-09-24
AU715338B2 (en) 2000-01-20
RU2229288C2 (ru) 2004-05-27
EP0841946A1 (en) 1998-05-20
IL122733A0 (en) 1998-08-16
ES2186796T5 (es) 2009-04-01
WO1997004807A1 (en) 1997-02-13
CA2226624A1 (en) 1997-02-13
ATE225185T1 (de) 2002-10-15
CN101172100A (zh) 2008-05-07
DE69624116T2 (de) 2003-06-18
EP0841946B2 (en) 2008-10-15
PT841946E (pt) 2003-02-28

Similar Documents

Publication Publication Date Title
ES2186796T3 (es) Procedimiento para el tratamiento del asma alergica.
EP2267032A3 (en) Method of administering therapeutic polypeptides, and polypeptides therefor
CL2009002139A1 (es) Peptido sintetico que comprende la secuencia sec id no:6 y sec id no:7 de la proteina gp41 del virus vih con actividad antiretroviral.
ATE126441T1 (de) Pentigetide zur behandlung von nicht-ige- vermittelten entzündlichen erkrankungen.
ATE202706T1 (de) Verwendung von 9-deoxyprostaglandinderivaten zur behandlung von glaukom
TR199902426T2 (xx) Bitki b�ceklerinin kontrol�.
DE69839014D1 (de) Apolipoprotein a-i agonisten und deren verwendung zur behandlung dyslipidämischer erkrankungen
AR004357A1 (es) Compuestos de 1-fenil-2-dimetilaminometil-ciclohexan-1-ol, y procedimiento de preparacion para dichos compuestos.
DE69927960D1 (de) Epiallopregnanolon zur behandlung von krankheiten des cns
ES8602768A1 (es) Un procedimiento para la preparacion de nuevas n-(heterociclil biciclo)-4-piperidinaminas.
DE69837855D1 (de) Apolipoprotein-a-i-agonisten und ihre anwendung zum behandeln von dyslipidämischer erkrankung
DE69435307D1 (de) Bazillus Thuringiensis und dessen insektizide Proteine
DE69630955T2 (de) Immortalisierung bzw. desimmortalisierung von zellen
DE69731463D1 (de) Rekombinante ribonuklease proteine
NO963487L (no) Isolerte, tyrosinaseavledete peptider, samt anvendelser derav
DE69626816D1 (de) Verwendung von selegilin zur behandlung von gehörverlust bei säugetieren
WO2003027251A3 (en) Novel molecules of the pyrin domain protein family and uses thereof
FI961584A0 (fi) C-reaktiivisista proteiinifragmenteista johdetut oligopeptidit
PT782630E (pt) Gene da doenca poliquistica do rim
DE69632407D1 (de) Antikörper gegen l-selectin zur vorbeugung von multiplem organversagen und akuter organschädigung
AR020141A1 (es) Toxinas y genes pesticidas de cepas de bacillus laterosporus
EA200000875A1 (ru) Белки, взаимодействующие с каспазой-8
DK0713365T4 (da) Rugmel
DE60042273D1 (de) Antitumorantikörper, proteine und deren verwendung
ATE165594T1 (de) Triarylethylenderivate zur therapeutischen verwendung